Karyopharm Therapeutics (KPTI) EBT Margin (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported EBT Margin for 15 consecutive years, with 200.48% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT Margin fell 10237.0% year-over-year to 200.48%; the trailing twelve-month figure through Jun 2026 stood at 160.28% (down 7020.0% YoY), and the FY2025 full-year result was 134.18%, down 8155.0% from the prior year.
• EBT Margin rose to 200.48% in Q2 2026 per KPTI's latest filing, from 300.08% in the prior quarter.
• Across five years, EBT Margin topped out at 55.76% in Q2 2024 and bottomed at 300.08% in Q4 2025.
• Historically, EBT Margin has averaged 106.75% across 5 years, with a median of 98.11% in 2025.
• The sharpest annual moves came in 2022 and 2025: EBT Margin surged 15962 bps in 2022, then tumbled 19868 bps in 2025.
• Over 5 years, EBT Margin stood at 117.11% in 2022, then slipped by 6 bps to 124.32% in 2023, then rose by 18 bps to 101.4% in 2024, then tumbled by 196 bps to 300.08% in 2025, then jumped by 33 bps to 200.48% in 2026.
• According to Business Quant data, EBT Margin over the past three periods registered 200.48%, 300.08%, and 75.14% for Q2 2026, Q4 2025, and Q3 2025 respectively.